Quanterix (QTRX) Expected to Release Quarterly Earnings on Monday

Key Points

• Quanterix is expected to report Q3 2026 results before Monday’s market open, with analysts forecasting a loss of $0.42 per share and revenue of $33.85 million. The earnings call is scheduled for November 9 at 8:30 a.m. ET.
• The company’s previous quarter fell well short of expectations, reporting a $1.04-per-share loss versus the projected $0.41 loss and revenue of $32.91 million against estimates of $37.48 million.
• Quanterix shares opened at $2.90, near the lower end of their 52-week range, while analysts maintain a consensus “Reduce” rating with a $3.25 target price.

Quanterix (NASDAQ:QTRX - Get Free Report) is expected to release its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect the company to announce earnings of ($0.42) per share and revenue of $33.85 million for the quarter. Interested persons may review the information on the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Monday, November 9, 2026 at 8:30 AM ET.

Quanterix (NASDAQ:QTRX - Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.63). The firm had revenue of $32.91 million for the quarter, compared to analyst estimates of $37.48 million. Quanterix had a negative return on equity of 26.09% and a negative net margin of 80.25%.

Quanterix Price Performance

NASDAQ QTRX opened at $2.90 on Monday. The company has a market cap of $137.15 million, a P/E ratio of -1.10 and a beta of 1.02. The stock has a 50-day moving average of $2.99 and a two-hundred day moving average of $3.91. Quanterix has a 1-year low of $2.15 and a 1-year high of $8.77.

Analyst Ratings Changes

Several equities analysts have commented on QTRX shares. TD Cowen boosted their price target on shares of Quanterix from $3.00 to $3.50 and gave the stock a "hold" rating in a research note on Tuesday, October 13th. Canaccord Genuity Group lowered their target price on Quanterix from $4.00 to $3.00 and set a "hold" rating for the company in a research note on Monday, August 17th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Quanterix in a research note on Friday, August 7th. Finally, Wall Street Zen upgraded shares of Quanterix from a "sell" rating to a "hold" rating in a research note on Saturday, September 19th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Reduce" and a consensus target price of $3.25.

Quanterix Company Profile

Quanterix Corporation NASDAQ: QTRX is a life sciences company that develops ultra-sensitive digital immunoassay technologies for detecting and measuring biomarkers in blood and other biological samples. Its platform is designed to identify proteins and other molecules at very low concentrations, supporting research into disease biology, diagnosis, treatment response and drug development.

The company's principal technology, Simoa, uses digital detection methods to improve the sensitivity of immunoassays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.